Announced
Completed
Financials
Tags
Biotechnology
Single Bidder
Minority
biotechnology
Friendly
medical
Private Equity
medical research
Private
Completed
product research
Cross Border
Acquisition
United States
Venture Capital
Synopsis
Nextech Invest, a venture capital and private equity firm, led a $85m Series A round in Ambagon Therapeutics, a biotechnology company, with participation from RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, Mission BioCapital, and Surveyor Capital. “Our deep understanding of 14-3-3 biology has broad applications for drug discovery as it opens up disordered protein regions as therapeutic targets. Combined with our proprietary structural insights, curated chemical library, and bespoke drug discovery tools, our experienced drug development team is well placed to bring forward new medicines addressing previously undruggable targets,” Scott Clarke, Ambagon Chief Executive Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.